HomePress Releases Press Releases Explore more press releases Filter Topics Corporate Neuroscience Oncology Rare Diseases Period 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 Filter by X recent search Reset Showing: 1 – 5 of 20 Press Releases Show 05 10 20 30 40 50 Sort Descending Ascending 28 April 2025 28 April 2025 LinkedIn Facebook Health Canada approves IQIRVO® as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis 04 May 2022 04 May 2022 LinkedIn Facebook Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer 20 October 2021 20 October 2021 LinkedIn Facebook Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma 16 March 2021 16 March 2021 LinkedIn Facebook Health Canada Approves INCRELEX®, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents 04 May 2020 04 May 2020 LinkedIn Facebook Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program 12…4
LinkedIn
Facebook
LinkedIn